Literature DB >> 16263084

Zcchc8 is a glycogen synthase kinase-3 substrate that interacts with RNA-binding proteins.

Michael P Gustafson1, Markus Welcker, Harry C Hwang, Bruce E Clurman.   

Abstract

Phosphorylation of c-Myc on threonine 58 (T58) stimulates its degradation by the Fbw7-SCF ubiquitin ligase. We used a phosphorylation-specific antibody raised against the c-Myc T58 region to attempt to identify other proteins regulated by the Fbw7 pathway. We identified two predominant proteins recognized by this antibody. The first is Ebna1 binding protein 2, a nucleolar protein that, in contrast with a previous report, is likely responsible for the nucleolar staining exhibited by this antibody. The second is Zcchc8, a nuclear protein that is highly phosphorylated in cells treated with nocodazole. We show that Zcchc8 is directly phosphorylated by GSK-3 in vitro and that GSK-3 inhibition prevents Zcchc8 phosphorylation in vivo. Moreover, we found that Zcchc8 interacts with proteins involved in RNA processing/degradation. We suggest that Zcchc8 is a GSK-3 substrate with a role in RNA metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263084     DOI: 10.1016/j.bbrc.2005.10.090

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3.

Authors:  Markus Welcker; Elizabeth A Larimore; Lori Frappier; Bruce E Clurman
Journal:  Mol Cell Biol       Date:  2011-01-10       Impact factor: 4.272

2.  What Are the bona fide GSK3 Substrates?

Authors:  Calum Sutherland
Journal:  Int J Alzheimers Dis       Date:  2011-05-18

3.  A systems approach implicates nuclear receptor targeting in the Atp7b(-/-) mouse model of Wilson's disease.

Authors:  Phillip A Wilmarth; Kristopher K Short; Oliver Fiehn; Svetlana Lutsenko; Larry L David; Jason L Burkhead
Journal:  Metallomics       Date:  2012-05-08       Impact factor: 4.526

Review 4.  The distinct roles of zinc finger CCHC-type (ZCCHC) superfamily proteins in the regulation of RNA metabolism.

Authors:  Yishu Wang; Yu Yu; Yidan Pang; Haojun Yu; Wenqi Zhang; Xian Zhao; Jianxiu Yu
Journal:  RNA Biol       Date:  2021-05-04       Impact factor: 4.652

5.  GSK-3: Functional Insights from Cell Biology and Animal Models.

Authors:  Oksana Kaidanovich-Beilin; James Robert Woodgett
Journal:  Front Mol Neurosci       Date:  2011-11-16       Impact factor: 5.639

6.  RBM7 subunit of the NEXT complex binds U-rich sequences and targets 3'-end extended forms of snRNAs.

Authors:  Dominika Hrossova; Tomas Sikorsky; David Potesil; Marek Bartosovic; Josef Pasulka; Zbynek Zdrahal; Richard Stefl; Stepanka Vanacova
Journal:  Nucleic Acids Res       Date:  2015-04-07       Impact factor: 16.971

7.  A quantitative 14-3-3 interaction screen connects the nuclear exosome targeting complex to the DNA damage response.

Authors:  Melanie Blasius; Sebastian A Wagner; Chunaram Choudhary; Jiri Bartek; Stephen P Jackson
Journal:  Genes Dev       Date:  2014-09-04       Impact factor: 11.361

8.  p38MAPK/MK2-mediated phosphorylation of RBM7 regulates the human nuclear exosome targeting complex.

Authors:  Christopher Tiedje; Michal Lubas; Mohammad Tehrani; Manoj B Menon; Natalia Ronkina; Simon Rousseau; Philip Cohen; Alexey Kotlyarov; Matthias Gaestel
Journal:  RNA       Date:  2014-12-18       Impact factor: 4.942

9.  A conserved virus-induced cytoplasmic TRAMP-like complex recruits the exosome to target viral RNA for degradation.

Authors:  Jerome M Molleston; Leah R Sabin; Ryan H Moy; Sanjay V Menghani; Keiko Rausch; Beth Gordesky-Gold; Kaycie C Hopkins; Rui Zhou; Torben Heick Jensen; Jeremy E Wilusz; Sara Cherry
Journal:  Genes Dev       Date:  2016-07-15       Impact factor: 11.361

10.  RNA profiles of porcine embryos during genome activation reveal complex metabolic switch sensitive to in vitro conditions.

Authors:  Olga Østrup; Gayla Olbricht; Esben Østrup; Poul Hyttel; Philippe Collas; Ryan Cabot
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.